Skip to main content

Advertisement

SpringerLink
Log in

Advances in radiation therapy for testicular seminoma

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Novel techniques and advances in radiation therapy (RT) have been explored to treat testicular seminoma, a highly radiosensitive and curable histology. We evaluated the historical and current indications for radiation therapy (RT) in testicular seminoma.

Methods

A narrative literature review was performed. Studies of RT for testicular seminoma were included. Additionally, recent trials testing the use of combination or surgical therapies for clinical stage (CS) II were included. Search parameters included radiation therapy, testicular seminoma, surgery, and chemoradiation. Parameters and outcomes assessed were progression-free survival (PFS), overall survival (OS), acute toxicities, long-term sequelae, and rates of secondary malignancies.

Results

Practice defining and changing studies in the use or omission of radiation therapy for testicular seminoma were identified along with resultant changes in National Comprehensive Cancer Network (NCCN) and European guidelines. Recent trials in combined chemoradiation and upfront surgical approaches to CS II disease were reviewed.

Conclusion

RT has historically been used as adjuvant treatment for CS I disease and is highly effective at treating CS II (A/B) testicular seminoma. The drive to maintain therapeutic efficacy and reduce acute and long-term side effects, namely secondary malignancies, is being tested using new radiation technologies, combined modality therapy in the form of chemoradiation and with upfront surgical approaches. Also, as guidelines now “strongly prefer” surveillance instead of adjuvant RT for CS I disease, the current CS II population comprises patients presenting with CS II disease (“de novo”) and those who present with CSII after relapsing post orchiectomy for CS I (“relapsed”). Emerging evidence suggests that these two groups have different outcomes with respect to RT and chemoradiation. Consequently, future trials may need to sub-stratify according to these groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cahill GF (1948) Cancer of kidneys, adrenals and testes. J Am Med Assoc 138:415–425. https://doi.org/10.1001/jama.1948.62900060004008

    Article  CAS  PubMed  Google Scholar 

  2. Boctor ZN, Kurohara SS, Badib AO, Murphy GP (1969) Current results from therapy of testicular tumors. Cancer 24:870–875. https://doi.org/10.1002/1097-0142(196911)24:5%3c870::aid-cncr2820240503%3e3.0.co;2-2

    Article  CAS  PubMed  Google Scholar 

  3. Amin MB, Edge SB, Greene FL et al (2018) AJCC cancer staging manual. Springer International Publishing

    Google Scholar 

  4. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708

    Article  PubMed  Google Scholar 

  5. Powles TB, Bhardwa J, Shamash J et al (2005) The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 95:1197–1200. https://doi.org/10.1111/j.1464-410X.2005.05504.x

    Article  PubMed  Google Scholar 

  6. Bray F, Richiardi L, Ekbom A et al (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118:3099–3111. https://doi.org/10.1002/ijc.21747

    Article  CAS  PubMed  Google Scholar 

  7. McGlynn KA, Devesa SS, Sigurdson AJ et al (2003) Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97:63–70. https://doi.org/10.1002/cncr.11054

    Article  PubMed  Google Scholar 

  8. Schafer EJ, Jemal A, Wiese D et al (2022) Disparities and trends in genitourinary cancer incidence and mortality in the USA. Eur Urol. https://doi.org/10.1016/j.eururo.2022.11.023

    Article  PubMed  Google Scholar 

  9. Ghazarian AA, Trabert B, Devesa SS, McGlynn KA (2015) Recent trends in the incidence of testicular germ cell tumors in the United States. Andrology 3:13–18. https://doi.org/10.1111/andr.288

    Article  CAS  PubMed  Google Scholar 

  10. Dieckmann K-P, Richter-Simonsen H, Kulejewski M et al (2018) Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol Int 100:409–419. https://doi.org/10.1159/000488284

    Article  CAS  PubMed  Google Scholar 

  11. (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594–603. https://doi.org/10.1200/JCO.1997.15.2.594

  12. Smalley SR, Earle JD, Evans RG, Richardson RL (1990) Modern radiotherapy results with bulky stages II and III seminoma. J Urol 144:685–689. https://doi.org/10.1016/s0022-5347(17)39555-1

    Article  CAS  PubMed  Google Scholar 

  13. Mead GM, Fossa SD, Oliver RTD et al (2011) Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 103:241–249. https://doi.org/10.1093/jnci/djq525

    Article  PubMed  Google Scholar 

  14. Fosså SD, Horwich A, Russell JM et al (1999) Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146. https://doi.org/10.1200/JCO.1999.17.4.1146

    Article  PubMed  Google Scholar 

  15. Jones WG, Fossa SD, Mead GM et al (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on medical research council trial TE18, European organisation for the research and treatment of cancer trial 30942 (ISRCTN18525328). J Clin Oncol 23:1200–1208. https://doi.org/10.1200/JCO.2005.08.003

    Article  PubMed  Google Scholar 

  16. Oliver RTD, Mason MD, Mead GM et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300. https://doi.org/10.1016/S0140-6736(05)66984-X

    Article  CAS  PubMed  Google Scholar 

  17. Nayan M, Jewett MAS, Hosni A et al (2017) Conditional Risk of relapse in surveillance for clinical stage I testicular cancer. Eur Urol 71:120–127. https://doi.org/10.1016/j.eururo.2016.07.013

    Article  PubMed  Google Scholar 

  18. Choo R, Thomas G, Woo T et al (2005) Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 61:736–740. https://doi.org/10.1016/j.ijrobp.2004.06.209

    Article  PubMed  Google Scholar 

  19. Oldenburg J, Berney DM, Bokemeyer C et al (2022) Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:362–375. https://doi.org/10.1016/j.annonc.2022.01.002

    Article  CAS  PubMed  Google Scholar 

  20. Gilligan T, Lin DW, Aggarwal R et al (2019) Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:1529–1554. https://doi.org/10.6004/jnccn.2019.0058

    Article  CAS  PubMed  Google Scholar 

  21. Guidelines detail. In: NCCN. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1468. Accessed 24 Jul 2023

  22. Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ (2012) Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys 83:e445–e452. https://doi.org/10.1016/j.ijrobp.2012.01.044

    Article  PubMed  Google Scholar 

  23. Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European germ cell cancer consensus group (EGCCCG): part I. Eur Urol 53:478–496. https://doi.org/10.1016/j.eururo.2007.12.024

    Article  PubMed  Google Scholar 

  24. Classen J, Schmidberger H, Meisner C et al (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21:1101–1106. https://doi.org/10.1200/JCO.2003.06.065

    Article  PubMed  Google Scholar 

  25. Chung PWM, Gospodarowicz MK, Panzarella T et al (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45:754–759. https://doi.org/10.1016/j.eururo.2004.01.020. (discussion 759–60)

    Article  PubMed  Google Scholar 

  26. Patterson H, Norman AR, Mitra SS et al (2001) Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol 59:5–11. https://doi.org/10.1016/s0167-8140(00)00240-1

    Article  CAS  PubMed  Google Scholar 

  27. Hallemeier CL, Pisansky TM, Davis BJ, Choo R (2013) Long-term outcomes of radiotherapy for stage II testicular seminoma–the Mayo clinic experience. Urol Oncol 31:1832–1838. https://doi.org/10.1016/j.urolonc.2012.03.010

    Article  PubMed  Google Scholar 

  28. Hanks GE, Peters T, Owen J (1992) Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 24:913–919. https://doi.org/10.1016/0360-3016(92)90475-w

    Article  CAS  PubMed  Google Scholar 

  29. Zagars GK, Pollack A (2001) Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51:643–649. https://doi.org/10.1016/s0360-3016(01)01701-1

    Article  CAS  PubMed  Google Scholar 

  30. Lederman GS, Sheldon TA, Chaffey JT et al (1987) Cardiac disease after mediastinal irradiation for seminoma. Cancer 60:772–776. https://doi.org/10.1002/1097-0142(19870815)60:4%3c772::aid-cncr2820600411%3e3.0.co;2-a

    Article  CAS  PubMed  Google Scholar 

  31. Huddart RA, Norman A, Shahidi M et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523. https://doi.org/10.1200/JCO.2003.04.173

    Article  CAS  PubMed  Google Scholar 

  32. Zagars GK, Ballo MT, Lee AK, Strom SS (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22:640–647. https://doi.org/10.1200/JCO.2004.05.205

    Article  PubMed  Google Scholar 

  33. Giannatempo P, Greco T, Mariani L et al (2015) Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes†. Ann Oncol 26:657–668. https://doi.org/10.1093/annonc/mdu447

    Article  CAS  PubMed  Google Scholar 

  34. Paly JJ, Lin CC, Gray PJ et al (2016) Management and outcomes of clinical stage IIA/B seminoma: results from the national cancer data base 1998–2012. Pract Radiat Oncol 6:e249–e258. https://doi.org/10.1016/j.prro.2016.05.002

    Article  PubMed  Google Scholar 

  35. Rosen DB, Ghosh A, Niemierko A et al (2023) Clinical outcomes of de novo versus relapsed early metastatic testicular seminoma treated with contemporary radiation therapy. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2023.09.010

    Article  PubMed  Google Scholar 

  36. Daneshmand S, Cary C, Masterson T et al (2023) Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol. https://doi.org/10.1200/JCO.22.00624

    Article  PubMed  Google Scholar 

  37. Martin JM, Joon DL, Ng N et al (2005) Towards individualised radiotherapy for stage I seminoma. Radiother Oncol 76:251–256. https://doi.org/10.1016/j.radonc.2005.08.005

    Article  PubMed  Google Scholar 

  38. Zilli T, Boudreau C, Doucet R et al (2011) Bone marrow-sparing intensity-modulated radiation therapy for stage I seminoma. Acta Oncol 50:555–562. https://doi.org/10.3109/0284186X.2011.564650

    Article  PubMed  Google Scholar 

  39. Hall EJ, Wuu C-S (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56:83–88. https://doi.org/10.1016/s0360-3016(03)00073-7

    Article  PubMed  Google Scholar 

  40. Choo R, Kazemba B, Choo CS et al (2018) Proton therapy for stage IIA-B seminoma: a new standard of care for treating retroperitoneal nodes. Int J Part Ther 5:50–57. https://doi.org/10.14338/IJPT-18-00001.1

    Article  PubMed  PubMed Central  Google Scholar 

  41. Pasalic D, Prajapati S, Ludmir EB et al (2020) Outcomes and toxicities of proton and photon radiation therapy for testicular seminoma. Int J Part Ther 7:11–20. https://doi.org/10.14338/IJPT-20-00018.1

    Article  PubMed  PubMed Central  Google Scholar 

  42. Simone CB 2nd, Ly D, Dan TD et al (2011) Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. Radiother Oncol 101:376–382. https://doi.org/10.1016/j.radonc.2011.05.028

    Article  PubMed  PubMed Central  Google Scholar 

  43. Efstathiou JA, Paly JJ, Lu H-M et al (2012) Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol 103:12–17. https://doi.org/10.1016/j.radonc.2012.01.012

    Article  PubMed  Google Scholar 

  44. Hoppe BS, Mamalui-Hunter M, Mendenhall NP et al (2013) Improving the therapeutic ratio by using proton therapy in patients with stage I or II seminoma. Am J Clin Oncol 36:31–37. https://doi.org/10.1097/COC.0b013e3182354b9e

    Article  CAS  PubMed  Google Scholar 

  45. Pursley J, Remillard K, Depauw N et al (2022) Radiation therapy for stage IIA/B seminoma: modeling secondary cancer risk for protons and VMAT vs. 3D photons. Int J Radiat Oncol Biol Phys 114:e250–e251. https://doi.org/10.1016/j.ijrobp.2022.07.1230

    Article  Google Scholar 

  46. Maxwell R, Chang Y, Paul C et al (2023) Cancer control, toxicity, and secondary malignancy risks of proton radiation therapy for stage I-IIB testicular seminoma. Adv Radiat Oncol 8:101259. https://doi.org/10.1016/j.adro.2023.101259

    Article  PubMed  PubMed Central  Google Scholar 

  47. Horwich A, Dearnaley DP, Sohaib A et al (2013) Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol 24:2104–2107. https://doi.org/10.1093/annonc/mdt148

    Article  CAS  PubMed  Google Scholar 

  48. Papachristofilou A, Bedke J, Hayoz S et al (2022) Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23:1441–1450. https://doi.org/10.1016/S1470-2045(22)00564-2

    Article  CAS  PubMed  Google Scholar 

  49. Unknown Publisher (2019) Reduced intensity radio-chemotherapy for stage IIA/B seminoma. Case Med Res. https://doi.org/10.31525/ct1-nct03937843

  50. Hiester A, Che Y, Lusch A et al (2023) Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol 84:25–31. https://doi.org/10.1016/j.eururo.2022.10.021

    Article  CAS  PubMed  Google Scholar 

  51. Heidenreich A, Seelemeyer F, Paffenholz P, Pfister DA (2023) Interim analysis of the prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadectomy in Metastatic Seminoma) trial. J Clin Oncol 41:409–409. https://doi.org/10.1200/JCO.2023.41.6_suppl.409

    Article  Google Scholar 

  52. Paly JJ, Efstathiou JA, Hedgire SS et al (2013) Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol 106:64–68. https://doi.org/10.1016/j.radonc.2012.12.002

    Article  PubMed  Google Scholar 

  53. Loriot Y, Texier M, Culine S et al (2022) The GETUG SEMITEP trial: de-escalating chemotherapy in good-prognosis seminoma based on fluorodeoxyglucose positron emission tomography/computed tomography. Eur Urol 82:172–179. https://doi.org/10.1016/j.eururo.2022.04.031

    Article  CAS  PubMed  Google Scholar 

  54. Chera BS, Kumar S, Beaty BT et al (2019) Rapid clearance profile of plasma circulating tumor HPV Type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res 25:4682–4690. https://doi.org/10.1158/1078-0432.CCR-19-0211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Regouc M, Belge G, Lorch A et al (2020) Non-coding microRNAs as novel potential tumor markers in testicular cancer. Cancers. https://doi.org/10.3390/cancers12030749

    Article  PubMed  PubMed Central  Google Scholar 

  56. Rüther U, Rothe B, Grunert K et al (1994) Role of human chorionic gonadotropin in patients with pure seminoma. Eur Urol 26:129–133. https://doi.org/10.1159/000475361

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Harvard Radiation Oncology Program, Boston, MA, USA

    Daniel B. Rosen

  2. Internal Medicine Residency Program, University of Hawaii, Honolulu, HI, USA

    Arvin Jeremy N. Tan

  3. Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

    Jennifer Pursley & Sophia C. Kamran

  4. Harvard Medical School, Boston, MA, USA

    Jennifer Pursley & Sophia C. Kamran

  5. Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Sophia C. Kamran

Authors
  1. Daniel B. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arvin Jeremy N. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennifer Pursley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sophia C. Kamran
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DBR: Manuscript writing/editing. AJNT: Manuscript writing/editing. JP: Manuscript writing/editing. SCK: Manuscript writing/editing.

Corresponding author

Correspondence to Sophia C. Kamran.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals & informed consent

NA.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosen, D.B., Tan, A.J.N., Pursley, J. et al. Advances in radiation therapy for testicular seminoma. World J Urol 41, 3895–3903 (2023). https://doi.org/10.1007/s00345-023-04674-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-023-04674-8

Keywords

Search

Navigation